Market Overview - Concerns over prolonged conflict in the Middle East have led to a surge in oil prices, with WTI crude surpassing $100 per barrel for the first time since 2022[1] - The US stock market showed mixed results, with the Dow Jones down 0.95% at 47,501.55 points, and the S&P 500 down 1.33% at 6,740.02 points[1] - The Shanghai Composite Index rose by 0.38% to 4,124.19 points, while the Shenzhen Component increased by 0.59%[1] Economic Indicators - The US non-farm payrolls unexpectedly decreased by 92,000 in February, raising concerns about a potential stagflation scenario as the unemployment rate rose to 4.4%[12] - Inflationary pressures are expected to complicate the Federal Reserve's interest rate decisions, with the market anticipating rates to remain unchanged in the upcoming meeting[12] Oil Market Dynamics - The ongoing conflict has disrupted oil trade routes, particularly through the Strait of Hormuz, leading to reduced production from major oil-exporting countries like Iraq and Kuwait[12] - The Trump administration has initiated a $20 billion maritime reinsurance plan to stabilize oil trade in the region amid rising prices[12] Sector Performance - The chemical sector showed strength, contributing to the overall market rebound in A-shares[1] - The Hong Kong market experienced volatility, with the Hang Seng Index closing up 1.72% at 25,757.29 points, driven by gains in technology and healthcare sectors[1] Corporate Developments - Yanzhou Coal Mining Company sold its 100% stake in Inner Mongolia Xintai Coal for RMB 3.05 billion, which is expected to positively impact its profits in 2026[15] - Longyuan Power reported a 0.73% year-on-year increase in power generation for February, with solar power generation up by 20.67%[15]

Core Viewpoint - The announcement by He Yu-B (02256) regarding the acceptance of the New Drug Application (NDA) for the oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijiemai (ABSK021), by the FDA marks a significant milestone for the treatment of TGCT patients [1][2]. Group 1: Drug Development and Approval - Beijiemai, developed by He Yu Pharmaceutical, has received FDA acceptance for its NDA, based on positive efficacy and safety results from the global Phase III MANEUVER study [1]. - The drug is expected to be commercially available globally through a partnership with Merck [1]. - Beijiemai was previously approved by the NMPA in China in December 2025 for symptomatic TGCT adult patients who may face functional limitations or severe complications from surgical removal [1]. Group 2: Clinical Efficacy and Safety - The Phase III study demonstrated statistically significant improvement in the objective response rate (ORR) for TGCT patients treated with Beijiemai, assessed at week 25 according to RECIST v1.1 standards [1]. - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reduced stiffness and pain [2]. - Long-term data from a median follow-up of 14.3 months indicated a continuous increase in ORR for patients who received Beijiemai treatment from the start of the study [3]. Group 3: Market Potential and Clinical Need - TGCT is a rare locally aggressive tumor that can lead to joint swelling, stiffness, and limited mobility, significantly impacting patients' daily activities and quality of life [3]. - If untreated or recurrent, TGCT can cause irreversible damage to bones, joints, and surrounding tissues [3]. - The ongoing regulatory submissions for Beijiemai in major global markets position the drug as a promising daily oral treatment option that is effective and well-tolerated, addressing unmet clinical needs in the TGCT field [3].

Core Viewpoint - The announcement highlights the acceptance of the New Drug Application (NDA) for the novel oral, highly selective, and effective small molecule CSF-1R inhibitor, Beijimai (ABSK021), by the FDA for the treatment of TGCT patients, indicating a significant advancement in addressing an unmet clinical need in this rare tumor type [1][2]. Group 1 - Beijimai is developed by Shanghai Heyu Biopharmaceutical Technology Co., Ltd. and is licensed to Merck for global commercialization [1]. - The NDA acceptance is based on positive efficacy and safety results from the global multi-center, randomized, double-blind, placebo-controlled Phase III MANEUVER study [1]. - The study demonstrated a statistically significant improvement in the objective response rate (ORR) for TGCT patients treated with Beijimai, assessed at week 25 according to RECIST v1.1 criteria [1]. Group 2 - All secondary endpoints related to key clinical outcomes for TGCT patients showed significant and clinically meaningful improvements, including enhanced joint range of motion and physical function, as well as reductions in stiffness and pain [2]. - Long-term data with a median follow-up of 14.3 months indicated a sustained increase in ORR for patients who received Beijimai treatment from the start of the study [2]. - TGCT is a rare locally aggressive tumor that can lead to joint swelling, stiffness, and limited mobility, significantly impacting patients' daily activities and quality of life [2].